Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYNACIRC CR vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Terminal half-life approximately 7-8 hours; sustained due to controlled-release formulation.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Primarily hepatic metabolism with biliary excretion; 20% renal, 80% fecal.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
>95%, primarily to albumin and alpha-1 acid glycoprotein.
92-98% bound primarily to albumin.
2.8 L/kg, indicating extensive tissue distribution.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral (CR): 20-30% due to first-pass metabolism.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
For GFR <30 m L/min, start at 2.5 mg orally once daily; titrate cautiously. No adjustment necessary for GFR >=30 m L/min.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
For Child-Pugh Class A or B: start at 2.5 mg orally once daily. For Child-Pugh Class C: avoid use due to lack of data.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Safety and effectiveness in pediatric patients have not been established.
Safety and efficacy not established; use is not recommended in pediatric patients.
Initial dose: 2.5 mg orally once daily. Titrate slowly due to increased sensitivity and risk of hypotension.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None
No FDA black box warning.
May cause hypotension, especially in volume-depleted patients,Peripheral edema,Hepatic impairment may require dose adjustment,May increase angina or myocardial infarction in patients with obstructive coronary disease upon initiation or dose escalation
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to isradipine or any component,Cardiogenic shock,Acute myocardial infarction
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Grapefruit juice increases isradipine plasma concentrations; avoid concurrent use. High-fat meals may slightly delay absorption but no significant clinical effect.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Isradipine (Dyna Circ CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times the maximum recommended human dose). However, embryotoxicity and fetotoxicity (increased resorptions, reduced fetal weight, delayed ossification) were observed at high doses. There are no adequate and well-controlled studies in pregnant women. Due to the potential risk of fetal harm, use only if the potential benefit justifies the risk. In the first trimester, avoid use if possible. In second and third trimesters, use with caution; may cause maternal hypotension and reduced uteroplacental perfusion.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Isradipine is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.6. Limited data suggest that infant exposure is low. However, due to the potential for adverse effects in the nursing infant (e.g., hypotension, cardiovascular effects), caution should be exercised. Use only if clearly needed and monitor the infant for signs of hypotension or bradycardia.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Pregnancy-induced pharmacokinetic changes (increased volume of distribution, increased renal clearance) may reduce isradipine concentrations. Empiric dose adjustment is not routinely recommended, but closer monitoring of blood pressure is advised. If inadequate response occurs, dose may be increased cautiously up to the maximum recommended dose (20 mg/day). No specific pregnancy dose adjustment guidelines exist; individualize therapy based on blood pressure response and tolerability.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
- DYNACIRC CR (isradipine controlled release) is a dihydropyridine calcium channel blocker used for hypertension. - The CR formulation allows once-daily dosing; avoid crushing or chewing tablets. - May cause dose-related peripheral edema, especially in higher doses or in elderly. - Use with caution in patients with aortic stenosis or in those with heart failure due to negative inotropic effects (though less than verapamil). - Grapefruit juice increases bioavailability; consider avoidance or dose adjustment. - Common side effects: headache, dizziness, flushing, and palpitations.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take exactly as prescribed once daily, preferably in the morning.,Swallow tablet whole; do not crush, chew, or split.,Avoid grapefruit juice while taking this medication.,Do not stop abruptly; may cause rebound hypertension.,Report persistent swelling in ankles/feet, palpitations, or severe dizziness.,May cause dizziness; avoid driving until you know how it affects you.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYNACIRC CR vs ADALAT CC, answered by our medical review team.
DYNACIRC CR is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that selectively inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, leading to vasodilation and reduced peripheral vascular resistance.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYNACIRC CR and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYNACIRC CR is: Isradipine extended-release (Dyna Circ CR) is indicated for hypertension. Initial dose: 5 mg orally once daily. Titrate based on blood pressure response; maximum dose 10 mg once daily.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYNACIRC CR and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYNACIRC CR is classified as Category C. Isradipine (DynaCirc CR) is a pregnancy category C drug. In animal studies, isradipine was not teratogenic in rats or rabbits at doses up to 150 mg/kg/day (approximately 100 times . ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.